Skip to main content
Fig. 3 | Journal of Translational Medicine

Fig. 3

From: VCP/p97 inhibitor CB-5083 modulates muscle pathology in a mouse model of VCP inclusion body myopathy

Fig. 3

Chronic CB-5083 treatment decreased muscle pathology in VCPR155H/R155H mice. A Hematoxylin and eosin (H&E) staining of myofibril structure in WT, and in vehicle and CB-5083-treated VCPR155H/R155H mice after a 5-month treatment. B, C Immunohistochemical analysis of TDP-43 in muscle sections of WT (n = 4), VCPR155H/R155H mice treated with vehicle (n = 3), and VCPR155H/R155H mice treated with CB-5083 (n = 4). TDP-43 cytoplasmic signals were reduced with less interstitial infiltration upon CB-5083 treatment. Arrowhead points to the interstitially infiltrating cells. D Quantification of the centralized nucleus in myofibril sections (n = 3 mice per group). E Quantification of myofibers with cytoplasmic TDP-43 signal in WT and VCPR155H/R155H mice upon CB-5083 treatment. Scale = 100 µm. Statistical analysis was performed by one-way ANOVA followed by Fisher’s LSD test: *P < 0.05, **P < 0.01

Back to article page